Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03557944
Other study ID # 4619
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 16, 2019
Est. completion date June 2024

Study information

Verified date March 2023
Source McMaster University
Contact Dee Mangin, MBChB, DPH, FRNZC, MD
Phone 905-525-9140
Email mangind@mcmaster.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In an aging population, most seniors suffer from multiple chronic conditions. When the number of medications taken is ≥5 (polypharmacy), the burden of taking multiple concurrent medications can do more harm than good. Seniors take an average of 7 regular medications and studies link polypharmacy with adverse effects on morbidity, function and health service use. However, it is not clear to what extent these are reversible if medication burden is reduced. This trial will test the effects on medication numbers and patient health outcomes of an intervention to polypharmacy. This study will test a program focused on medication reduction number and dose. Prioritizing medications according to the patient's preference as reducing the dose also reduces the risk of drug side effects. Patients, aged 70 years of age or older and taking ≥5 medications will receive the TAPER program. The program involves information gathering from the patient, including systematically seeking patients priorities and preferences, medication review with the pharmacist and then a consultation with the family doctor. The intervention is focused on discontinuing/reducing the dose of medications where possible using a 'pause and monitor' framework to assess the need for restart. An electronic program that detects drug adverse effects and flags potentially inappropriate medications will be integrated into an electronic clinical pathway incorporating monitoring and follow-up systems. This study will examine whether implementing a deprescribing care pathway with community pharmacists as point-of-entry can signal improvements in prescribing and patient health outcomes in older adults with polypharmacy.


Description:

This study uses a single-arm, longitudinal cohort feasibility design. Patients will receive the intervention following baseline data collection. Initial baseline data collection from the patient will include information on demographics, medications, and illness characteristics. The patient will then attend an appointment with a pharmacist to review medications appropriate for discontinuation/dose reduction, after which the patient will meet with their family physician to discuss patient preferences for discontinuation/dose reduction. Both health care providers will have access to TaperMD, a web-based program linked to evidence and tools to support reduction in polypharmacy. Follow-up research assessments will take place at one week, 3 months and 6 months (study end). Outcome assessments and a semi-structured interview will take place at the 6 month appointment.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date June 2024
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: - Aged 70 years of age or older - Patient must have a family doctor - Participating family doctor as most responsible provider - Currently taking 5 or more long-term medications - Has not had a recent comprehensive medication review - Patient willing to try discontinuation Exclusion Criteria: - English language or cognitive skills inadequate to understand and respond to rating scales - Terminal illness or other circumstance precluding 6 month study period

Study Design


Intervention

Other:
Medication reduction
Systematic approach to reduction in polypharmacy.

Locations

Country Name City State
Canada Dr. Dee Mangin Hamilton Ontario

Sponsors (4)

Lead Sponsor Collaborator
McMaster University Canadian Institutes of Health Research (CIHR), David Braley and Nancy Gordon Chair in Family Medicine, RxISK

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Successful discontinuation Mean difference in number of medications 6 months
Other Successful discontinuation or dose reduction Composite variable calculate to represent mean number of medications stopped or dose reductions 6 months
Other Successful discontinuation or dose reduction (proportion) Proportion of patients with successful discontinuation or dose reduction 6 month
Other Quality of life (EQ5D-5L) EuroQol five dimensions questionnaire (EQ5D-5L). Baseline, 6 months
Other Quality of life (SF36v2) The Short Form (36) Health Survey (SF-36-V2). Baseline, 6 months
Other Falls Total number of falls resulting in medication consultation or treatment recorded in hospital admission and primary care records, and by patient. Baseline, 6 months
Other Fatigue Avlund Mob-T Scale Baseline, 6 months
Other Pain severity and interference Brief Pain Inventory (Pain interference and Pain severity sub-scales) Baseline, 6 months
Other Sleep 15-D Scale (Sleep Question) Baseline, 6 months
Other Treatment Burden Brief Treatment Burden Scale Baseline, 6 months
Other Physical function capacity and ability (MANTY) Manty structured validated interview Baseline, 6 months
Other Physical function capacity and ability (balance) Global Rating of Change (Balance). Baseline, 6 months
Other Healthcare resource utilization (hospital admissions) Number of hospital admissions from administrative data and self-report; proportion of patients with at least one hospitalization. Baseline, 6 months
Other Healthcare resource utilization (ED/urgent care visits) Number of emergency department and urgent care visits from administrative data and self-report. Baseline, 6 months
Other Healthcare resource utilization (primary care visits) Number of primary care visits from administrative data Baseline, 6 months
Other Changes in medication side effects and symptoms (adverse) Patient self-report of appearance (new or worsening) of side effects associated with medications. 1 week, 3 month, 6 month
Other Changes in medication side effects and symptoms (positive) Patient self-report of disappearance (improvement or disappearance) of side effects associated with medications. 1 week, 3 month, 6 month
Other Serious adverse events Any event that requires in-patient hospitalization or prolongation of existing hospitalization, causes congenital malformation, results in persistent or significant disability or incapacity, is life-threatening or results in death (Health Canada (2011) Guidance Document for Industry - Reporting Adverse Reactions to Marketed Health Products). Baseline, 6 months
Other Implementation processes NoMAD survey Baseline, 3 months, 6 months
Other Pharmacists/family physician 5 best/worst aspects of intervention Open ended list 6 months
Other Pharmacists/family physician confidence in medication discontinuation 5 point Likert scale single question developed for study Baseline, 6 months
Other Pharmacists/family physician experiences with the deprescribing process Semi-structured interviews; field notes 6 months
Other Patient experience with deprescribing process (interview) Semi-structured interview 6 months
Other Satisfaction with intervention 5 point Likert scale single question developed for study 6 months
Other Satisfaction with care around medications 5 point Likert scale single question developed for study Baseline, 6 months
Primary Feasibility (recruitment number) Number of people who are invited to participate in the study. 6 months
Secondary Feasibility (proportion consented) Number of participants who consent divided by the number of potential participants invited. 6 months
Secondary Feasibility (proportion completed) Number of participants who complete 6-month data collection divided by the number of people who consented. 6 months
Secondary Feasibility (barriers to recruitment) Challenges to recruitment as identified by pharmacists via field notes and interviews. 6 months
Secondary Feasibility (time to complete surveys) Total time to complete all surveys Baseline, 6 months
Secondary Feasibility (capacity for pharmacist to implement) Challenges regarding implementation for pharmacists from field notes and interviews 6 months
Secondary Feasibility (issues with TaperMD tool) Communication between pharmacists and research team noting TaperMD issues from regular meetings. 6 months
Secondary Feasibility (missing data) Nature and percentage of missing data. 6 months
Secondary Feasibility (variance of measures) The calculated range of scores for surveys (where applicable) Baseline, 6 months
Secondary Feasibility (intervention implementation proportion) Number of plans containing deprescribing actions divided by the total number of plans. 6 months
See also
  Status Clinical Trial Phase
Completed NCT03688542 - Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module N/A
Completed NCT02545257 - Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care N/A
Withdrawn NCT01932632 - Medication Minimization for Long-term Care Residents N/A
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Active, not recruiting NCT04181879 - Appropriate Polypharmacy in Older People in Primary Care N/A
Not yet recruiting NCT03283735 - Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal N/A
Completed NCT02918058 - Reducing Post-discharge Potentially Inappropriate Medications Among Older Adults N/A
Completed NCT03655405 - Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents N/A
Completed NCT04575155 - Development & Pilot of the Technology-Enabled Alliance for Medication Therapy Management N/A
Withdrawn NCT05816967 - Rationalisation of Polypharmacy by the RASP-instrument and Discharge Counselling of Geriatric Inpatients N/A
Completed NCT05616689 - Bundled Hyperpolypharmacy Deprescribing N/A
Terminated NCT04055896 - Team Approach to Polypharmacy Evaluation and Reduction in a Long-Term Care Setting N/A
Active, not recruiting NCT03052192 - Biological Aging, Medication, Malnutrition and Inflammation Among Acutely Ill and Healthy Elderly.
Completed NCT02866799 - Multi-PAP: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy N/A
Completed NCT01732302 - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients N/A
Enrolling by invitation NCT05053815 - Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting
Active, not recruiting NCT04585191 - Reducing Treatment Risk in Older Adults With Diabetes N/A
Active, not recruiting NCT04120480 - Effectiveness of PGx Testing N/A
Recruiting NCT05609981 - Optimising Medication With Focus on Deprescribing in Frail Older People With Multidose Drug Dispensing Systems N/A
Recruiting NCT05501223 - Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic N/A